Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sri Harsha Tella & John Christopher Gallagher. (2014) Efficacy of desvenlafaxine succinate for menopausal hot flashes. Expert Opinion on Pharmacotherapy 15:16, pages 2407-2418.
Read now
Read now
Susan G Kornstein, Roger S McIntyre, Michael E Thase & Matthieu Boucher. (2014) Desvenlafaxine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 15:10, pages 1449-1463.
Read now
Read now
Elena M Umland & Laura Falconieri. (2012) Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. International Journal of Women's Health 4, pages 305-319.
Read now
Read now
Amos Pines. (2012) Climacteric. Climacteric 15:5, pages 500-510.
Read now
Read now
Articles from other publishers (28)
Kristin Rojas, Laura M. Spring, Liz O’Riordan & Anna Weiss. (2023) Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects. Annals of Surgical Oncology.
Crossref
Crossref
Abigail C WrightFrancesca L BeaudoinR. Brett McQueenKai YeungAshton MoradiSerina Herron-SmithEric GutierrezGrace A LinSteven D Pearson. (2023) The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council. Journal of Managed Care & Specialty Pharmacy 29:6, pages 692-698.
Crossref
Crossref
Tianyu Zhou. (2023) Estimation of placebo effect in randomized placebo-controlled trials for moderate or severe vasomotor symptoms: a meta-analysis. Menopause 30:1, pages 5-10.
Crossref
Crossref
Tobias De Villiers. (2022) The management of vasomotor symptoms of menopause (VMS) with menopausal hormone therapy (MHT). Current Opinion in Endocrine and Metabolic Research 27, pages 100420.
Crossref
Crossref
Kentaro Miyazaki, Masayuki KanekoMamoru Narukawa. (2022) Factors associated with high placebo response in clinical studies of hot flashes: a meta-analysis. Menopause 29:2, pages 239-246.
Crossref
Crossref
Sara J. Menown & Javier A. Tello. (2021) Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review. Advances in Therapy 38:10, pages 5025-5045.
Crossref
Crossref
A. Gosset, G. Robin, B. Letombe, J.-M. Pouillès & F. Trémollieres. (2021) Le traitement hormonal de la ménopause en pratique. RPC Les femmes ménopausées du CNGOF et du GEMVi. Gynécologie Obstétrique Fertilité & Sénologie 49:5, pages 358-372.
Crossref
Crossref
Mike Trower, Richard A. Anderson, Elizabeth Ballantyne, Hadine JoffeMary Kerr & Steve Pawsey. (2020) Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause 27:5, pages 498-505.
Crossref
Crossref
S Iliodromiti, W Wang, MA Lumsden, MS Hunter, R Bell, G Mishra & M Hickey. (2019) Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology 127:3, pages 320-333.
Crossref
Crossref
Srđan Milovanović & Milan Latas. (2020) Desvenlafaxine: Short review of selective antidepressant of class of selective inhibitors of reuptake of serotonine and noradraniline - SNRI. Engrami 42:1, pages 102-114.
Crossref
Crossref
Maria Celeste Osorio-Wender & Mona Lúcia Dall’Agno. 2019. Postmenopausal Diseases and Disorders. Postmenopausal Diseases and Disorders
295
303
.
Neil Majithia, Charles L. Loprinzi & Kathryn J. Ruddy. 2018. The Breast. The Breast
1024
1030.e4
.
JoAnn V. Pinkerton, Andrew G. Bushmakin, Joel Bobula, Joanne Lavenberg, Barry S. Komm & Lucy Abraham. (2017) Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies. Menopause 24:12, pages 1378-1385.
Crossref
Crossref
Lesley J. Scott. (2017) Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use. Drugs & Therapy Perspectives 33:10, pages 449-454.
Crossref
Crossref
Giulio Formoso, Enrica Perrone, Susanna Maltoni, Sara Balduzzi, Jack Wilkinson, Vittorio Basevi, Anna Maria Marata, Nicola Magrini, Roberto D'Amico, Chiara Bassi & Emilio Maestri. (2016) Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Mariam Lofty & Khaled Abdelmoez. (2016) Escitalopram versus black cohosh for relieving hot flashes in nondepressed menopausal women. Evidence Based Womenʼs Health Journal 6:3, pages 101-105.
Crossref
Crossref
Juergen Drewe, Kathleen A Bucher & Catherine Zahner. (2015) A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. SpringerPlus 4:1.
Crossref
Crossref
L. Guédra, A. Fèvre & O. Graesslin. (2015) Alternativas al tratamiento hormonal sustitutivo de la menopausia. EMC - Ginecología-Obstetricia 51:4, pages 1-12.
Crossref
Crossref
Susan G. KornsteinAnita H. ClaytonWeihang BaoChristine J. Guico-Pabia. (2015) A Pooled Analysis of the Efficacy of Desvenlafaxine for the Treatment of Major Depressive Disorder in Perimenopausal and Postmenopausal Women. Journal of Women's Health 24:4, pages 281-290.
Crossref
Crossref
. (2014) Practice Bulletin No. 141. Obstetrics & Gynecology 123:1, pages 202-216.
Crossref
Crossref
Thomas GuttusoJr.Jr.. (2013) Stellate ganglion block for treating hot flashes: A viable treatment option or sham procedure?. Maturitas 76:3, pages 221-224.
Crossref
Crossref
Kavita Krishna, Vandana Nimbargi & Bijoy Panda. (2013) Desvenlafaxine succinate: Is it a new promise and hope for management of vasomotor symptoms in postmenopausal women?. Apollo Medicine 10:2, pages 146-151.
Crossref
Crossref
William I. Fisher, Aimee K. Johnson, Gary R. Elkins, Julie L. Otte, Debra S. Burns, Menggang Yu & Janet S. Carpenter. (2013) Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA: A Cancer Journal for Clinicians 63:3, pages 167-192.
Crossref
Crossref
Renan Rocha, Joel Rennó Jr, Hewdy Lobo Ribeiro, Amaury Cantilino, Jerônimo de Almeida Mendes Ribeiro, Renata Demarque, Juliana Pires Cavalsan, Gislene Cristina Valadares & Antonio Geraldo da Silva. (2013) Tratamento da Depressão no Climatério. Debates em Psiquiatria 3:1, pages 18-25.
Crossref
Crossref
Zheng Sun, Yanqing Hao & Min Zhang. (2013) Efficacy and Safety of Desvenlafaxine Treatment for Hot Flashes Associated with Menopause: A Meta-Analysis of Randomized Controlled Trials. Gynecologic and Obstetric Investigation 75:4, pages 255-262.
Crossref
Crossref
David F. Archer, JoAnn V. Pinkerton, Christine J. Guico-Pabia, Eunhee Hwang & Ru-fong J. Cheng. (2013) Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause 20:1, pages 47-56.
Crossref
Crossref
JoAnn V. Pinkerton, David F. Archer, Christine J. Guico-Pabia, Eunhee Hwang & Ru-fong J. Cheng. (2013) Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms. Menopause 20:1, pages 38-46.
Crossref
Crossref
JoAnn V. Pinkerton, Ginger Constantine, Eunhee Hwang & Ru-fong J. Cheng. (2013) Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms. Menopause 20:1, pages 28-37.
Crossref
Crossref